LabGenomics

LabGenomics was founded in 2002 and listed on KOSDAQ in 2014 as a genomics-based molecular diagnostics company. In Korea it supplies PCR, MDx immunoassay, and NGS-based tests through a nationwide clinic and hospital network, covering prenatal screening and cancer genomic testing among other services.

The company acquired US pathology and molecular diagnostics firm QDx Pathology in 2023 and cancer diagnostics specialist IMD in 2024, entering the US clinical laboratory (CLIA Lab) market directly.

QDx accounts for roughly half of consolidated revenue and turned profitable on a standalone basis last year, two years after the acquisition.

In 2026 the company unified QDx and IMD's brand, sales organization, and management structure under the single 'LabGenomics' brand, now offering diagnostic testing across 27 US states and supplying services to major integrated delivery networks including Sutter Health and Adventist Health.

It also signed a license agreement with liquid-biopsy firm Dxome to supply the blood-cancer panel 'Hema655,' the minimal residual disease panel 'MRD30,' and the lymphoma circulating-tumor-DNA panel 'Lymphoma-ctDNA' in the US market.

The domestic business is shifting away from volume-driven growth toward profitability, trimming low-margin tests amid changes to specimen outsourcing rules and intensifying competition. Reflecting this restructuring, headcount fell 45.9% from 111 to 60 employees during the first half of 2026.

Annual revenue rose to KRW 144.8 billion in 2022 on pandemic-driven demand, with an operating margin of 45.7%, before plunging to KRW 73.1 billion in 2023 (operating margin -9.3%) and turning loss-making.

In 2024 revenue grew to KRW 85.9 billion year over year, yet the operating loss widened to KRW 18.5 billion (margin -21.5%), showing that a revenue recovery did not immediately translate into profitability improvement.

In 2025 revenue edged up 2.6% to KRW 88.2 billion, but the operating loss expanded sharply to KRW 53.5 billion (margin -60.7%) and the owners' net loss reached KRW 64.4 billion.

This was driven largely by one-off factors including bad-debt write-offs tied to delayed receivables collection, and the company has stated it is working to collect on roughly KRW 37.3 billion of bad-debt charges recognized in 2025.

On a quarterly basis, losses had been narrowing through Q3 2025 (revenue KRW 23.0 billion, operating loss KRW 2.1 billion), before a large one-off loss was concentrated in Q4 2025 (revenue KRW 20.9 billion, operating loss KRW 25.5 billion, owners' net loss KRW 40.9 billion).

In 2026, revenue continued to decline sequentially to KRW 17.9 billion in Q1 (operating loss KRW 4.2 billion) and KRW 15.8 billion in Q2 (operating loss KRW 6.9 billion), while the owners' net loss narrowed to KRW 2.5 billion in Q2 from KRW 4.7 billion in Q1.

Cumulative H1 2026 revenue fell 23.8% year over year to KRW 33.7 billion, and the operating loss shrank about 57% from KRW 25.9 billion to KRW 11.0 billion, as gross profit fell from KRW 15.5 billion to KRW 11.3 billion but selling and administrative expenses dropped sharply from KRW 41.4 billion to KRW 22.4 billion, largely reflecting a decline in bad-debt charges from KRW 16.6 billion to KRW 3.5 billion.

Management has stated it expects the improvement trend to become clearer from the third quarter as the bad-debt provision burden eases and the expanded US sales organization begins contributing more fully.

Korea's genomics and molecular diagnostics industry has entered a phase of intensifying competition as the pandemic-driven demand surge has faded, specimen-outsourcing rules have changed, and numerous providers have expanded NGS-based services.

In this environment, domestic diagnostics companies are shifting away from low-margin general-purpose tests toward higher-value-added areas such as prenatal and neonatal genetic disease screening and cancer gene panels.

The United States, the world's largest diagnostics market, presents high regulatory barriers to direct testing via CLIA Lab certification, but once established, providers can secure a stable revenue base through the insurance reimbursement system.

LabGenomics has built a nationwide CLIA lab network in the US through the QDx and IMD acquisitions and consolidated it under the single LabGenomics brand, pursuing a platform strategy spanning pathology, molecular diagnostics, and cancer diagnostics.

Blood cancer diagnostics and minimal residual disease (MRD) testing are considered high-value segments with strong repeat-testing demand, and the Dxome license agreement can be read as an attempt to expand LabGenomics's portfolio in this area.

However, the US diagnostics market includes large commercial laboratories and numerous regional CLIA labs, making insurer reimbursement contracting and sales-network expansion an ongoing challenge.

On the domestic capital-markets side, tightened listing-maintenance rules that took effect from August 2026—raising the KOSDAQ market-cap threshold to KRW 20 billion and introducing a new sub-KRW-1,000 penny-stock criterion—are affecting low-priced, small-cap biotech names broadly.

The company characterizes the period from 2025 through early 2026 as a restructuring phase intended to resolve most of the uncertainty tied to its legacy business. In H1 2026 it carried out cost restructuring, including scaling back low-margin domestic tests and cutting headcount 45.9% from 111 to 60 employees.

Management has said it expects revenue growth and profitability improvement to gain momentum from the second half, driven by strengthened QDx and IMD sales organizations and cost reductions.

As a new growth initiative, the company plans to expand supply of blood-cancer diagnostic panels (Hema655, MRD30, Lymphoma-ctDNA) in the US under its license agreement with Dxome.

Domestically, it has also outlined plans to broaden its high-value testing portfolio by introducing advanced overseas tests such as the blood-based Alzheimer's diagnostic 'Lumipulse.' On the capital-markets front, the company has approved a 1-for-5 share consolidation ahead of new-share listing on September 23, aiming to resolve the share-price criterion behind its administrative-issue designation.

However, because market capitalization itself is unchanged by the consolidation, concern over the separate market-cap-based administrative-issue criterion remains unresolved.